Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil

National Medical Journal of China

Volumn 89, Issue 4, 2009, Pages 251-253

  Lin, Bo ^a   Zhu, Yu Chun ^a   Lu, Yi Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Drug toxicity; Graft rejection; Kidney transplantation; Mycophenolic acid; Pharmacokinetics

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GRAFT INFECTION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; ADOLESCENT; ADULT; FEMALE; GRAFT REJECTION; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; YOUNG ADULT;

EID: 77954892950     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.04.010     Document Type: Article

References (9)

1. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet, 1995, 345: 1321-1325.
2. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation, 1992, 53: 428-432.
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention oi acute rejection in cadaveric renal transplantation. The Triconlinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation, 1996, 61: 1029-1037.
4. Van Gelder, T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safely and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation, 1999, 68: 261-266.
5. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem, 2001, 47: 1241-1248. (Pubitemid 32579112)
6. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol, 2002, 13: 759-768.
7. Mourad M, Wallemacq P, Konig J, et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet, 2002, 41: 319-327.
8. Krumme B, Wollenberg K, Kirste G, et al. Drug monitoring of mycophenolic acid in the early period after renal transplantation. Transplant Proc, 1998, 30: 1773-1774. (Pubitemid 28399312)
9. Hübner GI, Eismann R, Sziegoleit W. Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittelforschung, 2000, 50: 936-940.